Skip to main content
. 2017 Jul 25;22(8):1210. doi: 10.3390/molecules22081210

Figure 12.

Figure 12

Antitubercular 5-nitro-substituted heteroaryl chalcones prioritized by our QSAR-driven drug design strategy [139].